OTC:XAGE
Longevity Health Holdings, Inc.
A clinical-stage longevity biotechnology company with limited current revenue but high investment requirements for R&D.
Key Metrics
Investment Thesis
Bull Case
If the company successfully transitions its R&D pipeline into commercializable longevity products, the current valuation could reflect massive upside potential as the anti-aging market expands. The strategic focus on healthspan extension aligns with growing consumer interest in preventative health and biohacking solutions.
Bear Case
The company is burning through cash rapidly with a negative operating profit of -$5.0M and minimal revenue generation, creating an imminent threat of insolvency without further capital raises. Investors face high dilution risks as the firm relies on equity issuance to survive while posting significant losses year-over-year.
About Longevity Health Holdings, Inc.
Longevity Health Holdings, Inc. (XAGE) operates within the healthcare sector, focusing on longevity research and development initiatives. The company reports significant revenue in its fiscal year 2024 of $0.1M against a backdrop of substantial operating losses and high cash burn rates.
Analysis
Management Discussion
Management has incurred substantial losses, with net profit dropping to -$10.7M in the latest period from -$16.2M previously, while financing cash flows of $2.4M have been insufficient to cover operational deficits of $4.4M, leading to a net change in cash of -$2.8M and ending cash reserves depleted to only $157,139.
Industry Overview
The longevity health sector is emerging from early adoption into a growth phase, driven by demographic shifts toward aging populations and increased investment in biotechnology. Companies in this space currently operate at a loss to fund high-cost R&D before achieving product-market fit and revenue scalability.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $50.3K |
| Cost of Revenue | $0 | $0 | $6.4K |
| Gross Profit | $0 | $0 | $44.0K |
| Operating Expenses | $1.7M | $5.9M | $5.0M |
| Operating Income | $-1.7M | $-5.9M | $-5.0M |
| R&D | — | $2.5M | $1.1M |
| Marketing | — | — | $189.3K |
| Stock-Based Comp | — | $667.7K | $827.0K |
| D&A | — | $97.1K | $83.5K |
| Other OpEx | — | $3.4M | $3.8M |
| Non-Operating Income | $2.2M | $-10.3M | $-5.7M |
| Interest Expense | — | — | $29.4K |
| Pre-Tax Income | $596.2K | $-16.2M | $-10.7M |
| Income Tax | $391.2K | $0 | $-97.3K |
| Continuing Ops | $205.0K | $-16.2M | $-10.7M |
| Discontinued Ops | $0 | $760.2K | $-1.2M |
| Net Income | $205.0K | $-16.2M | $-10.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $205.0K | $-16.2M | $-10.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $285.2K | $62.9M | $955.6K |
| Cash & Equivalents | — | $2.9M | — |
| Accounts Receivable | — | — | $4.1K |
| Inventory | — | — | $108.7K |
| Other Current Assets | — | $60.0M | $842.8K |
| Long-Term Assets | $156.7M | $1.0M | $518.4K |
| PP&E (Net) | — | $192.8K | $113.9K |
| Operating Leases | — | $831.7K | $384.9K |
| Other LT Assets | — | $24.2K | $19.6K |
| Total Assets | $157.0M | $63.9M | $1.5M |
| Current Liabilities | $1.7M | $38.5M | $5.9M |
| Accounts Payable | — | $4.4M | $4.1M |
| Current Leases | — | $150.1K | $87.9K |
| Taxes Payable | $391.2K | — | — |
| Other Current Liab | $32.0K | $33.9M | $1.7M |
| Long-Term Liabilities | $5.4M | $697.7K | $309.9K |
| LT Operating Leases | — | $697.7K | $309.9K |
| Other LT Liab | — | $0 | $0 |
| Total Liabilities | $7.1M | $39.2M | $6.2M |
| Shareholders' Equity | $149.9M | $24.7M | $-4.7M |
| Paid-In Capital | $0 | $83.3M | $64.2M |
| Retained Earnings | $-6.0M | $-58.5M | $-68.9M |
| Total L&E | $157.0M | $63.9M | $1.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $205.0K | $-16.2M | $-10.7M |
| Non-Cash Adjustments | $-1.7M | $26.6M | $12.9M |
| Working Capital Changes | $956.6K | $-18.8M | $-6.7M |
| Cash from Operations | $-488.7K | $-8.3M | $-4.4M |
| Capital Expenditures | — | $30.5K | — |
| Cash from Investing | $0 | $-30.5K | $-748.8K |
| Share Buybacks | — | $0 | — |
| Cash from Financing | $-97.8K | $11.2M | $2.4M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-586.5K | $2.8M | $-2.8M |
| Beginning Cash | $774.2K | $128.1K | $2.9M |
| Ending Cash | $187.7K | $2.9M | $157.1K |
Frequently Asked Questions
How does Longevity Health Holdings, Inc. make money?
The company's primary financial activity revolves around research and development expenses totaling $1.1M, alongside minimal cost of revenue at $6,357, suggesting a focus on early-stage product development rather than established commercial sales streams.
What are the main risks for XAGE?
Severe liquidity crisis with negative cash flow from operations of $4.4M and a net profit deficit of $10.7M; significant dilution risk with common share issuances of $2.7M against a retained earnings deficit of $68.9M; high operating expenses relative to negligible revenue; and limited current assets compared to total liabilities.
What is XAGE's competitive advantage?
Potential access to proprietary longevity data, strategic partnerships in the biotech sector, and specialized expertise in extending healthspan as the market for anti-aging therapies matures.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.